Takuwa, Haruko http://orcid.org/0000-0002-2897-8700
Tsuji, Wakako
Yamamoto, Yoshihiro
Yamauchi, Chikako
Yotsumoto, Fumiaki
Article History
Received: 24 June 2018
Accepted: 10 September 2018
First Online: 18 September 2018
Change Date: 3 September 2019
Change Type: Correction
Change Details: In the original publication, in Table 1, the patient 3, 58 years of age, was scheduled to be administered eribulin after gemcitabine as adjuvant therapy.
Compliance with ethical standards
:
: No conflicts of interest relevant to this article are reported.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from the patient in this study.